This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
-
Research Site, Birmingham, Alabama, United States, 35211
Research Site, Sheffield, Alabama, United States, 35660
Research Site, Phoenix, Arizona, United States, 85020
Research Site, Tucson, Arizona, United States, 85741
Research Site, Little Rock, Arkansas, United States, 72212
Research Site, Bakersfield, California, United States, 93301
Research Site, Fountain Valley, California, United States, 92708
Research Site, Fullerton, California, United States, 92835
Research Site, Huntington Beach, California, United States, 92647
Research Site, Los Angeles, California, United States, 90025
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 80 Years
ALL
No
AstraZeneca,
2026-01-29